Pasithea Enterprise Value Multiple from 2010 to 2025

KTTAW Stock  USD 0.02  0  9.90%   
Pasithea Therapeutics Enterprise Value Multiple yearly trend continues to be fairly stable with very little volatility. Enterprise Value Multiple will likely drop to 0.0002 in 2025. During the period from 2010 to 2025, Pasithea Therapeutics Enterprise Value Multiple regression line of quarterly data had mean square error of  0.51 and geometric mean of  0.72. View All Fundamentals
 
Enterprise Value Multiple  
First Reported
2010-12-31
Previous Quarter
0.00024351
Current Value
0.000231
Quarterly Volatility
1.05688589
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Pasithea Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pasithea Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 783 K, Other Operating Expenses of 9.9 M or Total Operating Expenses of 15 B, as well as many indicators such as Price To Sales Ratio of 36.39, Dividend Yield of 83.34 or PTB Ratio of 2.0E-4. Pasithea financial statements analysis is a perfect complement when working with Pasithea Therapeutics Valuation or Volatility modules.
  
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Latest Pasithea Therapeutics' Enterprise Value Multiple Growth Pattern

Below is the plot of the Enterprise Value Multiple of Pasithea Therapeutics Corp over the last few years. It is Pasithea Therapeutics' Enterprise Value Multiple historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pasithea Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Enterprise Value Multiple10 Years Trend
Slightly volatile
   Enterprise Value Multiple   
       Timeline  

Pasithea Enterprise Value Multiple Regression Statistics

Arithmetic Mean2.15
Geometric Mean0.72
Coefficient Of Variation49.26
Mean Deviation0.86
Median2.72
Standard Deviation1.06
Sample Variance1.12
Range2.7166
R-Value(0.76)
Mean Square Error0.51
R-Squared0.57
Significance0.0007
Slope(0.17)
Total Sum of Squares16.76

Pasithea Enterprise Value Multiple History

2025 2.31E-4
2024 2.44E-4
2023 0.45
2022 1.27

About Pasithea Therapeutics Financial Statements

Pasithea Therapeutics investors use historical fundamental indicators, such as Pasithea Therapeutics' Enterprise Value Multiple, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Pasithea Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Pasithea Stock Analysis

When running Pasithea Therapeutics' price analysis, check to measure Pasithea Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pasithea Therapeutics is operating at the current time. Most of Pasithea Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pasithea Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pasithea Therapeutics' price. Additionally, you may evaluate how the addition of Pasithea Therapeutics to your portfolios can decrease your overall portfolio volatility.